Text Size
22 studies found for:    ANGPT2

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Withdrawn A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma
Condition: Glioblastoma
Intervention: Biological: PF-04856884
2 Completed The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis
Conditions: Inflammatory Lung Diseases;   Hemoptysis
Intervention:
3 Terminated PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Interventions: Biological: PF-04856884;   Drug: AG-013736
4 Active, not recruiting A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
Conditions: Solid Tumor;   Kidney Neoplasms;   Advanced Renal Cell Carcinoma
Interventions: Drug: CVX-060 + sunitinib;   Drug: Sunitinib
5 Recruiting Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial
Condition: Severe Malaria
Intervention: Drug: Inhaled Nitric Oxide
6 Completed Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors
Conditions: Advanced Solid Tumors;   Neoplasms;   Carcinoma;   Cancer;   Malignancy
Intervention: Biological: CVX-060
7 Completed Recurrence and Distant Metastases in Hepatocellular Carcinoma Treated by Transcatheter Arterial Chemoembolization
Condition: Hepatocellular Carcinoma
Intervention:
8 Terminated A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors
Conditions: Advanced Solid Tumors;   Epithelial Ovarian Cancer (EOC) or Primary Peritoneal Cancer (PPC)
Intervention: Drug: CVX-241
9 Recruiting The EPOCH Study (Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients With Hypertension)
Condition: CKD II-III
Interventions: Drug: Eplerenone;   Drug: Placebo
10 Unknown † The Role of Angiopoietin, Tie-2, and Vascular Endothelial Growth Factor (VEGF) in Sepsis-Induced Multiple Organ Dysfunction Syndrome (MODS)
Conditions: Sepsis;   Multiple Organ Dysfunction Syndrome
Intervention:
11 Completed Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors
Condition: Messurement Levels of VEGF
Intervention:
12 Active, not recruiting Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer
Condition: Rectal Cancer
Interventions: Drug: Bevacizumab + Capecitabine + Radiotherapy;   Drug: Capecitabine + Radiotherapy
13 Recruiting Laboratory Testing for Tie-2 Expressing Monocytes (TEMs) in Blood
Conditions: Advanced Cancer;   Healthy
Intervention:
14 Recruiting AMG 386 and Abiraterone for Advanced Prostate Cancer
Conditions: Prostatic Neoplams;   Prostate Cancer;   Neoplasm, Prostate;   Neoplasm,Prostatic
Interventions: Drug: AMG 386;   Drug: Abiraterone;   Drug: Prednisone
15 Terminated Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Stage II Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Drug: paclitaxel;   Biological: bevacizumab;   Drug: carboplatin;   Other: laboratory biomarker analysis
16 Recruiting Ozurdex for Retinal Vein Occlusion Study (ORVO Study)
Condition: Retinal Vein Occlusion
Intervention: Drug: dexamethasone implant
17 Unknown † Safety and Preliminary Efficacy of L-Arginine in Severe Falciparum Malaria
Condition: Severe Falciparum Malaria
Interventions: Drug: L-arginine hydrochloride;   Other: Normal saline
18 Recruiting Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Biological: trebananib;   Drug: cytarabine;   Other: laboratory biomarker analysis;   Other: pharmacological study
19 Completed Endothelial Dysfunction and Diabetes
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Trinitrin;   Drug: Neosynephrine 10% collyrium;   Drug: Iontophoresis with acetylcholine delivery;   Device: Dynamic Vessel Analyzer
20 Enrolling by invitation Plasma Angiopoietin Levels in Children Following Cardiopulmonary Bypass
Condition: Congenital Heart Defects
Intervention:
To Top

Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results
† Indicates status has not been verified in more than two years